Jesse Berry, MD

Director, Ocular Oncology and Retinoblastoma Program

Vice Chair, Academic Affairs, Department of Surgery

A. Linn Murphree, MD, Chair in Ocular Oncology

Children’s Hospital Los Angeles

Associate Professor of Ophthalmology, Keck School of Medicine of USC

Jesse Berry, MD, is the Director of Ocular Oncology and the Retinoblastoma Program at Children’s Hospital Los Angeles. She completed a fellowship at Children’s Hospital Los Angeles under the mentorship of Dr. Kim and A. Linn Murphree, MD, who founded the Retinoblastoma Program at Children’s Hospital Los Angeles. Dr. Berry’s retinoblastoma research is supported by the National Cancer Institute.

Clinical Interests

Retinoblastoma, Choroidal Melanoma, Ocular Oncology, Clinical Outcomes

Education

Medical School

Harvard Medical School, Boston, MA, Doctor of Medicine

Internship

Memorial Sloan Kettering Cancer Center, Transitional Intern, New York, NY

Residency

Doheny Eye Institute, University of Southern California Ophthalmology, Los Angeles, CA

Fellowship

Children’s Hospital Los Angeles, University of Southern California, Ocular Oncology and Oculoplastic Surgery, Los Angeles, CA

Accomplishments

Professional Memberships

American Academy of ophthalmology, 2009-present

Association for Research in Vision & Ophthalmology, 2009-present

International Society of Ocular Oncology, 2008-present

American Society of Cataract and Refractive Surgery, 2012-present

Women in Ophthalmology, 2012-present

California Association of Eye Physicians and Surgeons, 2011-present

Los Angeles Society of Ophthalmology, 2011-present

Society of Heed Fellows, 2013-present

Awards

Harvard College Scholarship: Elizabeth Cary Agassiz Scholar, 2000-2004

Malcolm Kinsberg Scholarship, 2000-2004; Kappa Alpha Theta Foundation Scholarship, 2002

David Rockefeller Center of Latin American Studies Grant, 2003

Nevil & Louise Ford Scholarship Fund, 2004-2008

Harvard Medical International Initiatives in Research Grant, 2005

Center for Eye Research and Education McCleary Grant, 2007

Doheny Eye Institute Medical Knowledge Award, 2011

Starr Schulman Fellowship, 2012

Department of Health Services Innovation Grant, 2012

Heed Ophthalmic Foundation Fellow, 2013-2014

Society of Heed Fellows, 2013

University of Southern California Excellence in Resident Teaching Award, 2013

University of Southern California Excellence in Resident Teaching Award, 2014

University of Southern California Excellence in Resident Teaching Award, 2018

Publications

Berry JL, Jubran R, Kim JW, Wong KE, Almarzouki H*, Lee TC, Murphree AL. Long term Outcomes of Group D Eyes in Bilateral Retinoblastoma Patients Treated with Chemoreduction and Low-dose IMRT Salvage. Pediatr Blood Cancer. 60(4):688-93, 2013. PMID#22997170

Berry JL, Kogachi K*, Aziz HA, McGovern K, Zolfaghari E*, Murphree AL, Jubran R, Kim JW. Risk of Metastasis and Orbital Recurrence in Advanced Retinoblastoma Eyes Treated with Systemic Chemoreduction versus Primary Enucleation. Pediatr Blood Cancer. 64(4), 2017. PMID#28221729 Co-initiated the project, executed data collection, primary composer of manuscript

Berry JL, Bechtold M*, Shah S*, Zolfaghari E*, Reid M, Jubran R, Kim JW. Not all seeds are created equal: Seed Classification is Predictive of Outcomes in Retinoblastoma. Ophthalmology. 124(12): 1817-25, 2017. PMID#28655537

Berry JL, Shah S*, Bechtold M*, Zolfaghari E*, Jubran R, Kim JW. Long-term Outcomes of Group D Retinoblastoma Eyes during the Intravitreal Melphalan Era. Pediatr Blood Cancer. 64(12), 2017. PMCID#28646513

Berry JL, Xu L, Murphree AL, Krishnan S, Stachelek K, Zolfoghari E*, McGovern K, Lee TC, Carlsson A, Kuhn P, Kim JK, Cobrinik D, Hicks J. Potential of Aqueous Humor as a Surrogate Biopsy for Retinoblastoma. JAMA Ophthalmol. 135(11): 1221-1230, 2017. PMID#29049475, PMCID#PMC5710399

PubMed Link

Publications on PubMed

Research

Jesse Berry, MD, and Liya Xu, PhD, are principal investigators of the Aqueous Humor Liquid Biopsy Laboratory.

Evaluation of the aqueous humor for tumor-derived genetic information and its application to prognosis and precision medicine for retinoblastoma patients. Investigating new methods of chemotherapy delivery for the treatment of Retinoblastoma. Evaluating treatment outcomes for Retinoblastoma eyes. This includes evaluation of treatment outcomes after systemic chemotherapy and the elucidation of factors present at diagnosis, which contribute to final visual outcome in eyes treated for retinoblastoma.